ORAL LEVODOPA DOSE-RESPONSE STUDY IN MPTP-INDUCED HEMIPARKINSONIAN MONKEYS - ASSESSMENT WITH A NEW RATING-SCALE FOR MONKEY PARKINSONISM

被引：93

作者：

KURLAN, R

KIM, MH

GASH, DM

机构：

[1] Department of Neurology, University of Rochester School of Medicine, Rochester, New York

[2] Department of Neurobiology and Anatomy, University of Rochester School of Medicine, Rochester, New York

来源：

MOVEMENT DISORDERS | 1991年 / 6卷 / 02期

关键词：

Levodopa; MPTP; Parkinsonism; Rating scale; Rhesus monkeys;

D O I：

10.1002/mds.870060205

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Quantitative measures for the severity of MPTP-induced parkinsonism and response to antiparkinsonian interventions in monkeys have been lacking. We carried out an oral levodopa dose-response study in two rhesus monkeys whose left hemiparkinsonism was induced by intracarotid administration of MPTP. A newly developed clinical rating scale of monkey parkinsonism showed a consistent dose-response relationship for levodopa over the dosage range of 50-3,500 mg/day. Antiparkinsonian effects appeared at 200 mg/day and were optimal at 1,000-2,000 mg/day. Levodopa also reversed rotational behavior, improved movement times for both the impaired and opposite upper limb, and produced dyskinesias at high dosages. Thus, MPTP-induced hemiparkinsonism in monkeys closely resembles the human disease condition, is associated with sensitive response measures, and should prove valuable for assessing novel antiparkinsonian therapies.

引用

页码：111 / 118

页数：8

共 16 条

[1]

Burns RS, Chiveh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ., A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N‐methyl‐4‐phenyl‐1, 2, 3, 6‐tetrahydropyridine, Proc Natl Acad Sci USA, 80, pp. 4546-4550, (1983)

[2]

Langston JW, Ballard P, Tetrud JW, Irwin I., Chronic parkinsonism in humans due to a product of meperidine‐analog synthesis, Science, 219, pp. 979-980, (1983)

[3]

Jenner P, Rupniak NMJ, Rose S, Et al., 1‐Methyl‐4‐phenyl‐1‐2‐3‐6‐tetrahydropyridine‐induced parkinsonism in the common marmoset, Neurosci Lett, 50, pp. 85-90, (1984)

[4]

Bankiewicz KS, Oldfield EH, Chiveh CC, Doppman JL, Jacobowitz DM, Kopin IJ., Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1‐methyl‐4‐phenyl‐1, 2, 3, 6‐tetrahydropyridine (MPTP), Life Sci, 39, pp. 7-16, (1986)

[5]

Jenner P., MPTP‐induced parkinsonism: the relevance to idiopathic Parkinson's disease, Disorders of movement: clinical, pharmacological and physiological aspects, pp. 157-175, (1989)

[6]

Eidelberg E, Brooks BA, Morgan WW, Walden JG, Kokemoor RH., Variability and functional recovery in the N‐methyl‐4‐phenyl‐1, 2, 3, 6‐tetrahydropyridine model of parkinsonism in monkeys, Neuroscience, 18, pp. 817-822, (1986)

[7]

Waters CM, Hunt SP, Jenner P, Marsden CD., An immunohistochemical study of the acute and long‐term effects of 1‐methyl‐4‐phenyl‐1, 2, 3, 6‐tetrahydropyridine in the marmoset, Neuroscience, 23, pp. 1025-1039, (1987)

[8]

Kurlan R, Kim MH, Gash DM.

[9]

Forno LS, Langston JW, DeLanney LE, Irwin I, Ricaurte GA., Locus ceruleus lesions and eosinophilic inclusions in MPTP‐treated monkeys, Ann Neurol, 20, pp. 449-455, (1986)

[10]

Mitchell IJ, Cross AJ, Sambrook MA, Crossman AR., Sites of the neurotoxic action of 1‐methyl‐4‐phenyl‐1, 2, 3, 6‐tetrahydropyridine in the macaque monkey include the ventral tegmented area and the locus coeruleus, Neurosci Lett, 61, pp. 195-200, (1985)

← 1 2 →